Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK to buy food allergy drug maker RAPT in $2.2bn deal
07:20am, Tuesday, 20'th Jan 2026
US-based biotech firm is developing treatment for allergies such as nuts, milk and eggs in children and adults
GSK To Acquire RAPT Therapeutics In $2.2 Billion Bet On Food Allergy Breakthrough
05:54am, Tuesday, 20'th Jan 2026
GSK plc to acquire RAPT Therapeutics Inc. for $58.00 per share, with an estimated upfront investment of $1.9 billion.
GSK announces $2.2 billion deal, targeting once-per-three-month food allergy drug
05:07am, Tuesday, 20'th Jan 2026
The growing scourge of food allergies drove U.K. heavyweight GSK to announce a $2.2 billion deal on Tuesday.
GSK snaps up food allergy drug specialist RAPT for $2.2bn
03:20am, Tuesday, 20'th Jan 2026
GSK PLC (LSE:GSK, NYSE:GSK) has struck a $2.2 billion deal to buy US biotech firm RAPT Therapeutics, adding a potential new treatment for food allergies to its pipeline. The acquisition gives GSK rig
DAEJEON, South Korea, Jan. 20, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of
GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments
02:48am, Tuesday, 20'th Jan 2026
The drugmaker said it agreed to pay RAPT shareholders $58 per share, with $1.9 billion upfront investment in cash.
GSK to buy RAPT Therapeutics for $2.2 billion
02:11am, Tuesday, 20'th Jan 2026
GSK said on Tuesday that it would acquire U.S.-based RAPT Therapeutics for $2.2 billion.
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
08:40am, Friday, 16'th Jan 2026
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high
Here's Why GSK (GSK) is a Strong Value Stock
10:40am, Thursday, 15'th Jan 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GSK plc (GSK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:46pm, Tuesday, 13'th Jan 2026
GSK plc (GSK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Tempus Shares Jump After Strong Preliminary 2025 Results
01:35pm, Monday, 12'th Jan 2026
Tempus AI (TEM) shares rose about 10% on Monday after the company filed preliminary, unaudited results showing roughly $1.27 billion in 2025 revenue.The filing
Why GSK (GSK) is a Top Growth Stock for the Long-Term
10:47am, Monday, 12'th Jan 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK Still Has Room To Run Despite Vaccine Cyclicality
09:00am, Monday, 12'th Jan 2026
GSK's growth is increasingly specialty-led (HIV, RI&I, oncology), not just vaccines. ViiV's long-acting injectables also tap into durable demand. Recent launches/approvals like Blenrep in r/r myeloma
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc (“GSK”, LSE/NYSE: GSK) to evaluate ivonesc
Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth
05:47am, Monday, 12'th Jan 2026
Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.
